A Prescription for Achieving Equitable Access to Antiobesity Medications.
作者信息
Wright Davene R, Guo Jingchuan, Hernandez Inmaculada
机构信息
Department of Population Medicine, Harvard Medical School and Harvard Pilgrim Health Care Institute, Boston, Massachusetts.
Department of Pharmaceutical Outcomes and Policy, College of Pharmacy, University of Florida, Gainesville.
出版信息
JAMA Health Forum. 2023 Apr 7;4(4):e230493. doi: 10.1001/jamahealthforum.2023.0493.
Abstract
摘要
相似文献
1
A Prescription for Achieving Equitable Access to Antiobesity Medications.
JAMA Health Forum. 2023 Apr 7;4(4):e230493. doi: 10.1001/jamahealthforum.2023.0493.
2
Low adoption of weight loss medications: A comparison of prescribing patterns of antiobesity pharmacotherapies and SGLT2s.
Obesity (Silver Spring). 2016 Sep;24(9):1955-61. doi: 10.1002/oby.21533.
3
An efficient approach to expand equitable access to antiobesity medications: deprescribing after weight loss plateau.
Am J Manag Care. 2024 Aug;30(8):348-350. doi: 10.37765/ajmc.2024.89586.
4
Antiobesity Medication Use in 2.2 Million Adults Across Eight Large Health Care Organizations: 2009-2015.
Obesity (Silver Spring). 2019 Dec;27(12):1975-1981. doi: 10.1002/oby.22581. Epub 2019 Oct 11.
5
Antiobesity drugs in the management of type 2 diabetes: A shift in thinking?
Cleve Clin J Med. 2017 Jul;84(7 Suppl 1):S39-S46. doi: 10.3949/ccjm.84.s1.05.
6
Treatment of obesity: Pharmacotherapy trends in the United States from 1999 to 2010.
Obesity (Silver Spring). 2015 Aug;23(8):1721-8. doi: 10.1002/oby.21136.
7
Rise in antiobesity drug prescribing for children and adolescents in the UK: a population-based study.
Br J Clin Pharmacol. 2009 Dec;68(6):844-51. doi: 10.1111/j.1365-2125.2009.03528.x.
8
Use of prescription antiobesity drugs in the United States.
Pharmacotherapy. 2013 Dec;33(12):1299-307. doi: 10.1002/phar.1342. Epub 2013 Sep 9.
9
National trends in the use and costs of anti-obesity medications in England 1998-2005.
J Public Health (Oxf). 2007 Jun;29(2):199-202. doi: 10.1093/pubmed/fdm013. Epub 2007 May 10.
10
Pharmacogenomics of Medication-Induced Weight Gain and Antiobesity Medications.
Obesity (Silver Spring). 2021 Feb;29(2):265-273. doi: 10.1002/oby.23068.
引用本文的文献
1
Synergistic Integration of Multimodal Metabolic and Bariatric Interventions Transforming Transplant Care.
J Clin Med. 2025 Aug 11;14(16):5669. doi: 10.3390/jcm14165669.
2
Uptake of and Disparities in Semaglutide and Tirzepatide Prescribing for Obesity in the US.
JAMA. 2025 Apr 29. doi: 10.1001/jama.2025.4735.
3
Perceptions of anti-obesity medications among people with obesity and healthcare providers in the US: Findings from the OBSERVE Study.
Obesity (Silver Spring). 2025 Jun;33(6):1076-1086. doi: 10.1002/oby.24290. Epub 2025 Apr 24.
4
TOWARD, a metabolic health intervention, demonstrates robust 1-year weight loss and cost-savings through deprescription.
Front Nutr. 2025 Feb 14;12:1548609. doi: 10.3389/fnut.2025.1548609. eCollection 2025.
5
Comparing clinical practice habits among obesity medicine physicians by patient, physician and clinic factors.
Obes Pillars. 2025 Jan 7;13:100157. doi: 10.1016/j.obpill.2025.100157. eCollection 2025 Mar.
6
Discontinuation and Reinitiation of Dual-Labeled GLP-1 Receptor Agonists Among US Adults With Overweight or Obesity.
JAMA Netw Open. 2025 Jan 2;8(1):e2457349. doi: 10.1001/jamanetworkopen.2024.57349.
7
Exploring Racial and Ethnic Differences in Utilization of Medications for Obesity Management in a Nationally Representative Survey.
J Racial Ethn Health Disparities. 2024 Dec 17. doi: 10.1007/s40615-024-02248-x.
8
Opportunities for General Internal Medicine to Promote Equity in Obesity Care.
J Gen Intern Med. 2024 Oct 16. doi: 10.1007/s11606-024-09084-z.
9
Behavioral risk factors and socioeconomic inequalities in ischemic heart disease mortality in the United States: A causal mediation analysis using record linkage data.
PLoS Med. 2024 Sep 17;21(9):e1004455. doi: 10.1371/journal.pmed.1004455. eCollection 2024 Sep.
10
One-Year Weight Reduction With Semaglutide or Liraglutide in Clinical Practice.
JAMA Netw Open. 2024 Sep 3;7(9):e2433326. doi: 10.1001/jamanetworkopen.2024.33326.
本文引用的文献
1
Impact of Real-Time Benefit Tools on Patients' Access to Medications: A Retrospective Cohort Study.
Am J Med. 2022 Nov;135(11):1315-1319.e2. doi: 10.1016/j.amjmed.2022.06.017. Epub 2022 Jul 24.
2
Managing Obesity: Scaling the Pyramid to Success.
Mayo Clin Proc. 2019 Jun;94(6):933-935. doi: 10.1016/j.mayocp.2019.04.011.
3
Prevalence of Obesity Among Adults, by Household Income and Education - United States, 2011-2014.
MMWR Morb Mortal Wkly Rep. 2017 Dec 22;66(50):1369-1373. doi: 10.15585/mmwr.mm6650a1.
4
Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial.
Lancet. 2011 Apr 16;377(9774):1341-52. doi: 10.1016/S0140-6736(11)60205-5. Epub 2011 Apr 8.
Zotero 插件